{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:10:51Z","timestamp":1760735451976,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejca.2020.05.012","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T05:06:14Z","timestamp":1594616774000},"page":"113-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma"],"prefix":"10.1016","volume":"136","author":[{"given":"Deepesh P.","family":"Lad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2020.05.012_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3026(19)30218-2","article-title":"Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study","volume":"7","author":"Vijenthira","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2020.05.012_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejca.2018.09.021","article-title":"Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?","volume":"104","author":"Shanbhag","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.05.012_bib3","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ejca.2020.05.012_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"year":"2020","series-title":"Brentuximab vedotin with chemotherapy for Stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","author":"Straus","key":"10.1016\/j.ejca.2020.05.012_bib5"},{"issue":"25","key":"10.1016\/j.ejca.2020.05.012_bib6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2020.05.012_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2020.05.012_bib8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2020.05.012_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2020.05.012_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.05.012_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.14379","article-title":"Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up","volume":"176","author":"Liu","year":"2017","journal-title":"Br J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:18Z","timestamp":1760732898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":11,"alternative-id":["S0959804920302781"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}